MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily 20+ Yr Trsy Bull 3X ETF

ProShares Ultra Silver

Direxion Daily Semicondct Bear 3X ETF

VanEck Vectors Junior Gold Miners ETF

T-REX 2X Inverse Tesla Daily Target ETF

VanEck Vectors Gold Miners ETF

GraniteShares 1.5x Long Coinbase Daily ETF

Mast Therapeutics, Inc.

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

GraniteShares 1.5x Long META Daily ETF

Volatility Shares Trust 2x Ether ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

GraniteShares 2x Long AMZN Daily ETF

Direxion Daily FTSE China Bull 3X ETF

Click Holdings Limited Ordinary Share

Foot Locker Inc.

Aytu BioPharma Inc.  Common Stock

Kindly MD Inc. Common Stock

LOBO EV TECHNOLOGIES LTD. Ordinary shares

Gryphon Digital Mining Inc Common Stock

Next Technology Holding Inc. Ordinary Shares

Siyata Mobile Inc. Common Shares

SolarEdge Technologies Inc. Common Stock

Asset Entities Inc. Class B Common Stock

Incannex Healthcare Limited American Depositary Shares

Crown LNG Holdings Limited Ordinary Shares

Luminar Technologies Inc.  Class A Common Stock

MicroAlgo Inc. Ordinary Shares

Dick's Sporting Goods Inc Common Stock

HWH International Inc. Common Stock

Plug Power Inc. Common Stock

UnitedHealth Group Incorporated Common Stock (DE)

ScanTech AI Systems Inc. Common stock

Twin Vee PowerCats Co. Common Stock

Click here to get full coverage on Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan

Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment  Stock Titan

Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan

Click here to get full coverage on ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus

ARQT: Key Insights from Genital Psoriasis Consensus Statements |  GuruFocus

ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...  Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail

Click here to get full coverage on Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts  simplywall.st

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

Click here to get full coverage on ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings - Nasdaq

ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings  Nasdaq

ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings - Nasdaq

Click here to get full coverage on Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha

Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade)  Seeking Alpha

Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates  MSN

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN

Click here to get full coverage on Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  Yahoo Finance

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Click here to get full coverage on Arcutis Promotes 20-Year Biotech Veteran to CFO Amid Strong ZORYVE Growth - Stock Titan

Arcutis Promotes 20-Year Biotech Veteran to CFO Amid Strong ZORYVE Growth  Stock Titan

Arcutis Promotes 20-Year Biotech Veteran to CFO Amid Strong ZORYVE Growth - Stock Titan

Click here to get full coverage on Arcutis Awards Major Stock Package: 26,500 RSUs to Three New Hires Under Nasdaq Rule - Stock Titan

Arcutis Awards Major Stock Package: 26,500 RSUs to Three New Hires Under Nasdaq Rule  Stock Titan

Arcutis Awards Major Stock Package: 26,500 RSUs to Three New Hires Under Nasdaq Rule - Stock Titan

Click here to get full coverage on Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - Nasdaq

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?  Nasdaq

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - Nasdaq

Click here to get full coverage on Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?  Yahoo Finance

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Click here to get full coverage on Arcutis Q1 2025 Earnings Preview: Key Metrics Coming for Fast-Growing Dermatology Innovator - Stock Titan

Arcutis Q1 2025 Earnings Preview: Key Metrics Coming for Fast-Growing Dermatology Innovator  Stock Titan

Arcutis Q1 2025 Earnings Preview: Key Metrics Coming for Fast-Growing Dermatology Innovator - Stock Titan

Click here to get full coverage on Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?  Yahoo Finance

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - Yahoo Finance

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%  Yahoo Finance

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - Yahoo Finance

Click here to get full coverage on Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher  Yahoo Finance

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?  Yahoo Finance

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance

Click here to get full coverage on Arcutis Announces Chief Financial Officer Transition - GlobeNewswire

Arcutis Announces Chief Financial Officer Transition  GlobeNewswire

Arcutis Announces Chief Financial Officer Transition - GlobeNewswire

Click here to get full coverage on Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?  Yahoo Finance

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News - Stock Titan

Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News  Stock Titan

Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News - Stock Titan

Click here to get full coverage on Arcutis Issues 27,000 RSUs: What This Employee Compensation Move Signals - Stock Titan

Arcutis Issues 27,000 RSUs: What This Employee Compensation Move Signals  Stock Titan

Arcutis Issues 27,000 RSUs: What This Employee Compensation Move Signals - Stock Titan

Click here to get full coverage on Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT)  Seeking Alpha

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Click here to get full coverage on ARQT Stock Hits 52-Week High at $16.32 Amidst Strong Yearly Growth - Investing.com

ARQT Stock Hits 52-Week High at $16.32 Amidst Strong Yearly Growth  Investing.com

ARQT Stock Hits 52-Week High at $16.32 Amidst Strong Yearly Growth - Investing.com

Click here to get full coverage on Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - simplywall.st

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up  simplywall.st

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - simplywall.st

Click here to get full coverage on Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037  Stock Titan

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Click here to get full coverage on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript  Insider Monkey

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - Stock Titan

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology  Stock Titan

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - Stock Titan

Click here to get full coverage on Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...  Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Click here to get full coverage on How Did Arcutis Transform ZORYVE Into a Revenue Powerhouse? Q4 Earnings Reveal 413% Growth - Stock Titan

How Did Arcutis Transform ZORYVE Into a Revenue Powerhouse? Q4 Earnings Reveal 413% Growth  Stock Titan

How Did Arcutis Transform ZORYVE Into a Revenue Powerhouse? Q4 Earnings Reveal 413% Growth - Stock Titan

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News - GuruFocus

Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News  GuruFocus

Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News - GuruFocus

Click here to get full coverage on New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus

New Consensus Statements on Impact of Genital Psoriasis on Patie  GuruFocus

New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus

Click here to get full coverage on How to Take Advantage of moves in (ARQT) - news.stocktradersdaily.com

How to Take Advantage of moves in (ARQT)  news.stocktradersdaily.com

How to Take Advantage of moves in (ARQT) - news.stocktradersdaily.com

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview - GuruFocus

Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview  GuruFocus

Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...  Yahoo Finance

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance

Click here to get full coverage on What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E - GuruFocus

What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E  GuruFocus

What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E - GuruFocus

Click here to get full coverage on Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets  Seeking Alpha

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News - GuruFocus

Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News  GuruFocus

Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News - GuruFocus

Click here to get full coverage on Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M - marketscreener.com

Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M  marketscreener.com

Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M - marketscreener.com

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations - GuruFocus

Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations  GuruFocus

Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period (ARQT) - Seeking Alpha

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period (ARQT)  Seeking Alpha

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period (ARQT) - Seeking Alpha

Click here to get full coverage on Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus

Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In  GuruFocus

Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus

Click here to get full coverage on Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand - GuruFocus

Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand  GuruFocus

Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million - GuruFocus

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million  GuruFocus

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million - GuruFocus

Click here to get full coverage on Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - simplywall.st

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?  simplywall.st

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - simplywall.st

Click here to get full coverage on What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

What's Going On With Arcutis Biotherapeutics Stock Monday?  Benzinga

What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

Click here to get full coverage on Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ)  Seeking Alpha

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Click here to get full coverage on Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - Investor's Business Daily

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone  Investor's Business Daily

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - Investor's Business Daily

Click here to get full coverage on Arcutis Strengthens Team with Strategic RSU Grants Worth Millions - Key Details Revealed - Stock Titan

Arcutis Strengthens Team with Strategic RSU Grants Worth Millions - Key Details Revealed  Stock Titan

Arcutis Strengthens Team with Strategic RSU Grants Worth Millions - Key Details Revealed - Stock Titan

Click here to get full coverage on Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com

Learn to Evaluate (ARQT) using the Charts  news.stocktradersdaily.com

Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com

Click here to get full coverage on Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P  GuruFocus

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News  GuruFocus

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus

Click here to get full coverage on Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  TradingView

Arcutis Biotherapeutics Inc (ARQT)

Price Chart

Key Statistics

Technicals

About ARQT

Latest News

Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan

ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers